Martin Gosling

Brighton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

The Concise Guide to PHARMACOLOGY 2025/26: Ion channels.

The Concise Guide to PHARMACOLOGY 2025/26: Ion channels.

Journal: British journal of pharmacology

Published: December 29, 2025

ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.

ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: August 27, 2025

Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.

Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.

Journal: European journal of medicinal chemistry

Published: August 15, 2024

The Tmem16a chloride channel is required for mucin maturation after secretion from goblet-like cells in the Xenopus tropicalis tadpole skin.

The Tmem16a chloride channel is required for mucin maturation after secretion from goblet-like cells in the Xenopus tropicalis tadpole skin.

Journal: Scientific reports

Published: February 26, 2024

ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.

ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 05, 2024

Niclosamide does not modulate airway epithelial function through blocking of the calcium activated chloride channel, TMEM16A.

Niclosamide does not modulate airway epithelial function through blocking of the calcium activated chloride channel, TMEM16A.

Journal: Frontiers in pharmacology

Published: January 11, 2023

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Journal: Journal of medicinal chemistry

Published: May 24, 2021

Reply to Olschewski et al.: TMEM16A Potentiation: Possible Drawbacks.

Reply to Olschewski et al.: TMEM16A Potentiation: Possible Drawbacks.

Journal: American journal of respiratory and critical care medicine

Published: May 29, 2020

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: May 21, 2020

Potentiating TMEM16A does not stimulate airway mucus secretion or bronchial and pulmonary arterial smooth muscle contraction.

Potentiating TMEM16A does not stimulate airway mucus secretion or bronchial and pulmonary arterial smooth muscle contraction.

Journal: FASEB bioAdvances

Published: May 11, 2020

Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.

Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.

Journal: International journal of chronic obstructive pulmonary disease

Published: April 08, 2020

TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?

TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?

Journal: International journal of molecular sciences

Published: March 04, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026